Drug General Information
Drug ID	D0F3PU
Former ID	DCL000535
Drug Name	Iboctadekin + Doxil
Indication	Ovarian cancer [ICD9: 183; ICD10:C56]		Phase 1	[522292], [550972]
Company	GSK
Structure
PubChem Compound ID	5478883, 31703
Target and Pathway
Target(s)	DNA topoisomerase II	Target Info	Inhibitor	[550963]
	Interleukin-18	Target Info	Modulator	[550963]
KEGG Pathway	Cytokine-cytokine receptor interaction
	NOD-like receptor signaling pathway
	Cytosolic DNA-sensing pathway
	Salmonella infection
	Legionellosis
	African trypanosomiasis
	Malaria
	Tuberculosis
	Influenza A
	Inflammatory bowel disease (IBD)
	Rheumatoid arthritis
NetPath Pathway	IL4 Signaling Pathway
PANTHER Pathway	Interleukin signaling pathway
	Toll receptor signaling pathway
Pathway Interaction Database	IL27-mediated signaling events
	IL12-mediated signaling events
	IL23-mediated signaling events
	Cellular roles of Anthrax toxin
	IL12 signaling mediated by STAT4
Reactome	Interleukin-1 processing
WikiPathways	Hypertrophy Model
	IL1 and megakaryotyces in obesity
	Corticotropin-releasing hormone
	NOD pathway
References
Ref 522292	ClinicalTrials.gov (NCT00659178) Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer. U.S. National Institutes of Health.
Ref 550972	Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 550963	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.